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Abstract: The importance of precise co- and post-transcriptional processing of RNA in the regulation
of gene expression has become increasingly clear. RNA-binding proteins (RBPs) are a class of proteins
that bind single- or double-chain RNA, with different affinities and selectivity, thus regulating the
various functions of RNA and the fate of the cells themselves. ELAV (embryonic lethal/abnormal
visual system)/Hu proteins represent an important family of RBPs and play a key role in the fate of
newly transcribed mRNA. ELAV proteins bind AU-rich element (ARE)-containing transcripts, which
are usually present on the mRNA of proteins such as cytokines, growth factors, and other proteins
involved in neuronal differentiation and maintenance. In this review, we focused on a member of
ELAV/Hu proteins, HuR, and its role in the development of neurodegenerative disorders, with a
particular focus on demyelinating diseases.
Keywords: RNA-binding proteins (RPBs); ELAV/Hu; HuR; neurodegenerative disease; neuroinflam-
mation; neuroprotection; glia; demyelination
1. Introduction
RNA is the link between DNA and proteins and contains all the information recovered
from DNA to regulate cellular functions and promote cell survival. The importance of
precise co- and post-transcriptional processing of RNA in the regulation of gene expression
has become increasingly clear. These are complex and controlled processes that lead to
mRNA maturation, which require the intervention and interaction of various components,
including RNA Binding Proteins (RBPs) [1].
RNA-bound proteins are a class of proteins that bind single- or double-chain RNA,
with different affinities and selectivity, thus regulating the various functions of RNA and
the fate of the cells themselves [2]. RBPs accompany and protect RNA from transcription
in pre-mRNA in the nucleus to nuclear export, up to translation into the cytoplasm [3].
RBPs interact with RNA by binding to sequences or structural motifs through a restricted
and structurally well-defined series of RNA-binding domains (RBDs) [2]. Each RBP can
contain one or more RBDs, which typically bind 2–6 nucleotides. Although the binding to
this small number of nucleotides is sufficient for a correct interaction, RNA can contain
more copies of the same domain, allowing the recognition of a larger and more complex
region, and increasing the specificity and affinity [4]. Through various in vitro and in vivo
studies, more than 1000 RBPs with different biological functions have been identified in
humans and mice [5]. They are involved in the coordination and stabilization of complexes
with proteins, the processing and maturation of mRNA, alternative splicing and splicing,
polyadenylation, transport and localization within the cell, stabilization, the silencing of
mature mRNA and in its degradation [6–8].
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Therefore, given the numerous processes in which RBPs are involved, a mutation
or alteration of their functions can lead to the development of diseases [9], such as neu-
rodegenerative pathologies [10], cardiovascular disease [11], tumors [12], and immune
system dysregulation [13]. Despite the breadth of RBPs discovered, many of them have
not been characterized yet and their biological function is unknown, and it is likely that
many RBPs are still to be discovered [1,5]. It is therefore important to adequately under-
stand their functioning, which could lead to the discovery and development of novel drug
candidates [14]. RBPs have been linked to diseases such as Alzheimer’s and Parkinson’s dis-
ease [15], autism spectrum [16], schizophrenia [17], and other central nervous system (CNS)
disorders. Specifically, the RBPs expressed in the CNS are mainly involved in alternative
splicing, the process that allows the obtainment of different isoforms of a protein, starting
from a single gene. Indeed, alternative splicing occurs more frequently in the nervous
system, rather than in other tissues, due to the complexity of neuronal activities, neuronal
growth and to the normal activity of synapses [18]. RBPs are also important to protect
mRNA from premature translation and degradation during transport from the neuronal
body to dendrites and axons, allowing the de novo synthesis of proteins at the synapse
level and guiding the transport itself [7]. Neurons have their own systems for regulating
RNA, and embryonic lethal/abnormal visual system (ELAV)/Hu proteins represent one
of the most investigated family belonging to the RPBs present in neurons. The ELAV/Hu
proteins represent an important family of RBPs and play a key role in the fate of newly
transcribed mRNA [19]. In Drosophila, the ELAV gene family encodes RBPs specifically
expressed in the nervous system and includes three genes, ELAV, RNA-binding protein 9
(rbp9), and fne (found in neurons). In mammals, the four ELAV-like proteins show a high
degree of conservation (70–85% identity). Three members, HuB (erlB), HuC (erlC), and
HuD (erlD), are specifically expressed in neurons [20]. They are mainly localized in the
cytoplasm, but the presence of some specific transporters, such as the transporting Trn1–2,
and of some nuclear factors (APRIL and CRM), mediates their translocation in and out
the nucleus [21]. The fourth member, HuR/HuA (elrA), is expressed ubiquitously in the
organism and is predominantly located in the nucleus. However, because of its shuttling
activity, HuR can also be found in the cytoplasm, and its subcellular distribution can change
physiologically during cell senescence, stress signals, and tumor growth [22]. The biolog-
ical function of ELAV RBPs has been identified in their ability to post-transcriptionally
control gene expression through cytoplasmic stabilization and/or the enhancement of the
translation of their mRNA targets. Structurally, they consist in two binding sites for RNA
and one site for binding polyadenylated sequences, separated by a highly variable region
that is involved in the interaction with other proteins and is important for receiving signals
on the nucleus-cytoplasmic transport, and vice-versa. This last region is generated by
alternative splicing to obtain different isoforms, which, while recognizing the same types
of RNA, can interact with each other and with other factors in a different way, which leads
to the formation of multimeric complexes of ribonucleoproteins. This heterogeneity is very
important, especially in the nervous system.
ELAV proteins bind AU-rich element (ARE)-containing transcripts, which are usually
present on the mRNA of proteins such as cytokines, growth factors and other proteins
involved in neuronal differentiation and maintenance [23]. The binding of ELAVs to
these sequences increases the stability of the RNA because it competes with proteins that
promote de-adenylation and, therefore, degradation by exonucleases [24]. In addition to
the stabilizing effect, these proteins are also involved in the mechanisms of transport to
cellular compartments far from the nucleus, such as axons or dendrites, contributing not
only to the differentiation of the nervous system, but also to its plasticity [25]. Moreover,
they intervene in the mechanisms of splicing and polyadenylation, influencing not only
the transcription of other RNAs, but also self-regulation [17]. Further insights into the
function of these proteins could help to understand the mechanisms underlying neuronal
development and functioning. Given the nature of RBPs, ELAVs influence the fate of many
mRNAs, modulating simultaneously many different physiological functions: nELAVs
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(HuD, HuB, HuC) accelerate neuronal differentiation and axonal outgrowth and modulate
neuronal integrity [26], while HuR promotes inflammation and the proper functioning of
the immune system [22].
2. Physiological Role of HuR outside the Nervous System
HuR can alter the cellular response to various stimuli (proliferative, stress, apoptotic,
differentiation, senescence, inflammatory, and immune) through post-transcriptional ad-
justments of specific mRNAs [22]. ELAV proteins have been thoroughly investigated for
their correlation with the insurgence of cancer. The most extensively studied RBP in cancer
is HuR. Malignant tumors express a higher amount of HuR than normal tissues or benign
tumors [27,28]. Moreover, high levels of HuR are directly related to the development of
larger malignant tumors [29] and chemoresistance to standard cancer therapies [30]. HuR
interacts with and/or regulates many transcripts involved in the development of cancer
cells, such as cyclins, matrix metalloproteinase-9 (MMP-9), metastasis-associated protein
1 (MTA1), anti-apoptotic protein pro-thymosin α (ProTalpha) and HIF-1α [31]. Indeed,
its downregulation leads to the reduction of tumor masses [32]. HuR can modulate the
expression of proteins involved in cell proliferation, angiogenesis, and myogenesis [32].
Another important role of HuR is related to the inflammatory processes. HuR controls
several mRNAs encoding pro-inflammatory cytokines (TNF-α and IL-6), stabilizing them
and promoting their expression in different cells of the immune system (i.e., fibroblasts,
T-cells, and macrophages) [33], and it is involved in several chronic inflammatory patholo-
gies, such as rheumatoid arthritis [34]. Moreover, HuR stabilizes the mRNAs that encode
one major pro-inflammatory mediator, the enzyme cyclooxygenase-2 (COX-2) [35], which
is expressed in several types of cancer. Indeed, HuR-silencing has been proposed as an
adjuvant therapeutic target in chemotherapy for pancreatic cancer [36]. HuR was found to
stabilize and increase nitric oxide synthase 2 (NOS2) expression in carcinomas of the lung
and colon [37]. Moreover, interleukin-10 (IL-10), a well-known anti-inflammatory cytokine,
can reduce the levels, and repress the action, of HuR. Thus, in a human monocytic cell line,
IL-10 destabilized the post-transcriptional mRNA expression of inflammatory cytokines,
and this effect depended on the ability of IL-10 to inhibit the expression of HuR [38]. HuR
has also been shown to play a role in cardiovascular pathologies [11]. It has been reported
to possess a functional role in the progression of pathological cardiac hypertrophy [39],
which is linked to an abnormal placental labyrinth vasculature [40]. Finally, it has been
reported that HuR induces the stabilization of angiogenic factor-encoding, the vascular
endothelial-derived growth factor (VEGF), and MMP-9 mRNAs [41]. Through HuR protein,
the alphavirus Sindbi reduces mRNA decay and maintain a highly productive infection [42].
Moreover, HuR may be involved in the reverse transcription reaction of the human im-
munodeficiency virus 1 (HIV-1) [43]. In muscle fibers from inclusion body myositis (IBM)
patients, both the poly(A)-binding protein 1 and HuR were found to aggregate in RNA
deposits; these observations were suggested to reflect an impairment in mRNA turnover
and translation in IBM [44]. During skeletal myogenesis, HuR coordinates the regulation
of muscle differentiation genes [45]. The activation of adenosine monophosphate AMP-
activated protein kinase (AMPK) results in HuR nuclear sequestration, the inhibition of
NOS2 synthesis, and a reduction in cytokines-induced MyoD loss. These results define
NOS2 and HuR as critical players in cytokines-induced cachexia, establishing them as
potential therapeutic targets [46].
3. HuR in the Nervous System: A Key Regulator of Neuroinflammation
Astrocytes and microglia are the first elements to respond to damage in the CNS. In
fact, these cells change their phenotypes from an anti- to pro-inflammatory state in response
to signals coming from the damaged site itself [47]. Chronic inflammation represents an
important protagonist in the development and progression of neurodegenerative diseases.
Indeed, a number of pro-inflammatory molecules have been detected in the brains of
patients with neurodegenerative diseases [48]. The presence of risk factors (genetic and
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environmental) leads to continuous and dis-regulated microglial activation, promoting a
chronically unregulated cell state. This loss of control through microglial activity leads to
the deterioration of the brain’s structure and functions [49]. The process by which microglia
change their shape, footprint, and physiology is defined as the activation of microglia,
during which these cells can switch from a pro-inflammatory to an anti-inflammatory
phenotype [50]. The anti-inflammatory phenotype is responsible for damage repair and
immunomodulation. In the case of prolonged neuroinflammation, the ability of microglia
to assume this progressive inactivation profile is limited, thus causing a state of chronic
activation [51]. Activated microglia can become harmful to the nervous system through
the secretion of inflammatory cytokines and chemokines [52,53]. There are numerous neu-
rodegenerative diseases characterized by strong microglial activation, such as Parkinson’s
disease, Alzheimer’s disease, and multiple sclerosis (MS). Therefore, chronic neuroinflam-
mation is considered a potential target for innovative therapeutic strategies [54]. Activated
astrocytes also play a crucial role in neuroinflammation and, through the release of cy-
tokines and chemokines, perform the main role of recruiting and activating other cells of
the immune system, such as neutrophils, monocytes, and microglia itself [55]. There is
growing evidence for the existence of heterogeneity among reactive astrocytes across differ-
ent brain regions, but also locally, within the same region, as regards astrocyte proliferation,
morphology and gene expression. Inflammatory mediators can drive astrocyte transcrip-
tome profiles towards pro-inflammatory phenotypes [56] that possess a protective effect
against microbial infection but can be harmful in neurodegenerative diseases [57]. Among
the inflammatory mediators released by microglia and astrocytes, tumor necrosis factor-α
(TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and matrix metalloproteases are the
most common. These factors further activate other glial cells, facilitate their mobility, and
attract immune cells circulating in the damaged area. The result is an amplification of the
production of pro-inflammatory factors, the accumulation of cytotoxic substances, the loss
of integrity of the blood-brain barrier (BBB), and, finally, cell death [58]. All these cellular
events are linked to the ubiquitous transcription factor nuclear factor-κB (NF-κB), which
is usually inactivated by inhibitory proteins, such as IκBα, in the cytoplasm. The main
activators of this factor are the products of cell damage and cytokines (TNF-α and IL-1β)
release. In general, NF-κB is involved in a wide range of biological processes underlying
inflammation and the immune response [59]. Neuroinflammatory processes in diseases
such as MS are closely related to the activity of the immune system. The involvement of
CD4 + T lymphocytes in the pathogenesis of many inflammatory and autoimmune dis-
eases has been demonstrated. These cells, once differentiated, assume different functions
and produce specific combinations of pro-inflammatory cytokines. Among the various
subtypes, Th17, which produces Interleukin-17 (IL-17), plays a role in the pathogenesis of
experimental autoimmune encephalomyelitis (EAE) and MS [60]. It has been shown, for
example, to stabilize pro-inflammatory cytokines in CD4 + T lymphocytes, leading to an
increased response in inflammatory diseases, such as EAE [61]. Often, studies concerning
the mechanisms and elements involved in cellular processes are based on the analysis of
the levels of mRNA and their protein derivatives. In many cases, there is no proportionality
between these two elements, which is why it is not possible to obtain correct information by
considering only transcriptomics studies [62]. Matsye et al. [63] demonstrated the involve-
ment of HuR in the molecular and cellular phenotype of activated microglia. Although it is
normally found in the nucleus, in the activated microglia of the spinal cord of mice and hu-
mans with amyotrophic lateral sclerosis (ALS), HuR is overexpressed and mainly localized
in the cytoplasm. The knockdown of HuR in microglial cells led to an attenuation of the
expression of factors in inflammation, chemotaxis and cell migration, which is less related
to a decrease in mRNA stability. On the contrary, this has been linked to the suppression of
the promoter activity of NF-κB transcription. It has also been shown that the involvement
of HuR in the translation processes, in some cases, may be independent of the stabilizing
effect on mRNA. An example is that the reduction of TNF-α levels is not associated with
the reduction of mRNA levels. Similar results were obtained by Kwan et al. [64], who
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evaluated the role of HuR in activated astrocytes in a model of spinal injury, where the
inhibition of HuR leads to a reduction of cytokines and chemoattraction for neutrophiles
and microglia [64]. Furthermore, HuR has been evaluated as a specialized controller of
oxidative stress in neurons to confer protection from neurodegeneration [65].
4. HuR in Neurodegenerative Disorders
In this review, we listed a series of chronic neurodegenerative diseases in which HuR is
reportedly involved. The experimental details about each disorder are reported in Table 1.
4.1. HuR and Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a neuromuscular disease characterized by
motor neuron degeneration, in which the chronic activation of microglia contributes to
disease progression [66,67]. Approximately 10% of ALS cases are hereditary, with a muta-
tion of copper-zinc superoxide dismutase 1 (SOD1) being the most frequently identified
genetic defect [68]. ELAV proteins are positive regulators of SOD1 gene expression; indeed,
the docking sites for these proteins have been found in SOD1 3’-untranslated region [68].
The role of HuR in the pathogenesis of ALS remains controversial. An increase of HuR
expression in peripheral blood mononuclear cells (PBMC), together with its upregulation
in the motor cortex or the spinal cord in ALS patients has been reported. In parallel, the
upregulation of SOD1 has been observed, suggesting that HuR could be involved in the
post-transcriptional phase of SOD1 gene expression [69]. Silencing HuR in the microglia
of ALS-associated mutant SOD1 mice reduced the release of pro-inflammatory cytokines.
These findings highlighted the important role of HuR in the phenotype of activated mi-
croglia, which could be exploited as a possible therapeutic target in ALS [63] (see Table 1).
Contrary to these results, other evidence suggested that HuR downregulation might lead
to an aggravation of disease. Indeed, HuR stabilizes and enhances the translation of
growth factors, and of VEGF. It has been reported that HuR increased VEGF expression
and reversed the impairment of mitochondrial function and oxidative stress, suggesting
that the impairment of HuR may accelerate CNS atrophy and cell death [68]. The role of
HuR in regulating two RBPs, namely TAR DNA-binding protein of 43 kDa (TDP-43) and
Fused in Sarcoma/Translocated in Liposarcoma (FUS/TLS), has been linked genetically
to ALS. About 4% of hereditary cases of ALS are due to mutations in TARDBP, the gene
that encodes TDP-43, a nuclear protein that regulates mRNA processing; and glial TDP-43
pathology is present in ALS [70]. Lu et al. [71] demonstrated that HuR regulates TDP-43
expression in astrocytes cells and that this cross-talking influences the phenotype of glia
cells. Another important aspect of ALS patients is the presence of severe metabolic dysfunc-
tion, characterized by hypermetabolism, hyperlipidemia, and glucose intolerance, which
lead to a drastic degeneration of the disease [72]. AMPK plays a key role in controlling
metabolism in the CNS, which is indeed modulated by AMP levels and cellular stress.
Altered AMPK activation was reported in the spinal cords of mice with mutant SOD1, and
abnormal localization of HuR was associated with enhanced AMPK in the motor neurons
of ALS patients, inducing an imbalance in the RNA metabolism and contributing to ALS
pathogenesis [73]. Energy deficits may contribute to motor neuron vulnerability in ALS,
suggesting that the modulation of energy balance may be a potential therapeutic approach.
4.2. HuR and Spinal Muscle Atrophy
Spinal Muscular Atrophy (SMA) is a neuromuscular disease characterized by the
degeneration of motor neurons in the spinal cord, caused by a mutation in the motor neuron
1 gene, SMN1. This mutation leads to the death of alpha-motoneurons, the reduction of
myogenesis and a loss of innervation, causing muscle weakness and atrophy [74]. HuR can
stabilize some important transcription factors, such as Myogenin, MyoD [75], acetylcholine
receptor beta (AChR β) subunit mRNAs [76], and p21 [45], which are involved in muscle
differentiation. To achieve these effects, HuR must accumulate in the cytoplasm. Thus,
the critical role of HuR in myogenesis necessarily involves the import factor Transportin
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2 (TRN2), which is activated by a caspase-dependent cleavage of a cytoplasmic HuR.
Indeed, HuR cleavage generates two fragments: HuR-cleavage product 1 (HuR-CP1) and 2
(HuR-CP2); HuR-CP1 is responsible for HuR accumulation in the cytoplasm [77]. However,
HuR-CP1 itself cannot induce myogenesis in the absence of full-length HuR, suggesting
that the effect on myogenin mRNA is indirect via HuR, and emphasizing the importance of
the remaining uncleaved cytoplasmic HuR in this process as a regulator of gene expression
for myogenesis factors. The importance of caspase-3 activation for muscle differentiation
has been described. It has been shown that during myogenesis, HuR could be cleaved by
this caspase [78]. While the role of HuR in the myogenesis process is partly understood, the
role of caspase-3 remains completely unclear. Another pathway that induces the cleavage
of HuR involves the stress-response kinase protein kinase dsRNA (PKR). PKR was shown
to be important for muscle differentiation because of its regulation of the p38 MAPK
and PI3K/Akt pathways [79]. PKR activates the FADD/caspase-8/caspase-3 pathway to
trigger HuR cleavage, without being phosphorylated [78]. P38 activators may be valuable
candidates for the management of SMA, as inducing p38 phosphorylation leads to an
increase of cytoplasmatic HuR levels. In the cytoplasm, HuR can interact with the 3′-UTR
of functional survival motor neuron (SMN) transcription [80]. Celecoxib, an FDA-approved
p38-activator, increased SMN quantity, improved motor function, and enhanced animal
survival, in a mouse model of SMA [81]. P38 is expressed much more in microglia than in
neurons and astrocytes. Thus, the effect of HuR could be mediated both by the regulation
of myogenesis and by the modulation of microglia activation.
4.3. HuR in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune inflammatory and neurodegenerative
disease of the CNS, characterized by demyelination, axonal loss and motor dysfunction,
that affects 2.9 million people worldwide [82]. Inflammation plays a central role in MS;
indeed, pro-inflammatory microglia are associated with the demyelization process [83,84],
through the release of cytokines and other mediators of inflammation, as well as oligoden-
drocyte degeneration and myelin loss [85–87]. MS progresses in different stages, beginning
with a cascade of inflammation. The pivotal spark to initiate this cascade seems to be
the migration of Th17 into the CNS across the BBB through disrupted tight junctions.
Consequently, glial cells are activated in the spinal cord, leading to the excessive release
of pro-inflammatory cytokines [88]. Therefore, targeting microglia could represent an
interesting focus for the development of novel therapeutical approaches. In the EAE model,
the repeated intrathecal administration of anti-HuR antisense oligonucleotide (ASO) re-
duced the main behavioral symptoms in mice, which reproduced the main clinical signs
seen in MS patients [89]. The intrathecal administration of anti-HuR ASO decreased
the proinflammatory-activated microglia, inflammatory infiltrates, the expression of the
proinflammatory cytokines IL-1β, TNF-α, and IL-17, and inhibited the activation of the
NF-κB pathway. The beneficial effect of anti-HuR ASO in EAE mice also corresponded to
decreased permeability of the BBB. In the spinal cord tissue of EAE mice, HuR expression
colocalized with activated microglia, and its inhibition led to a reduction of the microglia
pro-inflammatory phenotype [90]. Another important effect was that anti-HuR ASO ad-
ministration reduced the mechanical allodynia produced by the EAE model. This effect
was also observed in a peripheral model of neuropathic pain, in which HuR colocalized
with microglia cells and induced a shift from a pro-inflammatory to an anti-inflammatory
state [91]. HuR is ubiquitously expressed in PBMC, and its activity has been observed in
Th17 cells, which are deeply involved in the encephatoligenic process promoted by MS in
the CNS [92]. IL-17-producing Th17 cells are major contributors to chronic inflammatory
and autoimmune diseases, such as MS, rheumatoid arthritis, and inflammatory bowel dis-
ease. Mice with adoptively transferred HuR KO Th17 cells demonstrated delayed initiation
and reduced disease severity at the onset of EAE, compared with those with wild-type
Th17 cells [93]. The C-C chemokine receptor 6 (CCR6) is critical for pathogenic Th17 cell
migration to the CNS. The silencing of HuR reduced CCR6 expression in Th17 cell and
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reduced their migration to CNS in the EAE model, compared to the WT group [94]. HuR
altered the transcriptome of Th17 cells characterized by reduced levels of differentiation
factors (namely, RORγt, IRF4, and T-bet), thereby reducing the formation of pathogenic
IL-17+IFN-γ+CD4+ T cells in the spleen. These data have been confirmed by measuring the
activity of dihydrotanshinone I (DHTS), a well-known HuR inhibitor, that reduced Th17
differentiation, reducing the symptoms associated with the EAE model [95]. However, in
contrast with the above results, PBMCs from 52 MS patients demonstrated a lower HuR
protein content compared to 43 healthy controls, which continued to decline with the pro-
gression of the disease. These opposite expression levels might indicate that HUR performs
different roles depending on whether it is inside or outside the CNS, thus promoting neu-
roinflammation in the spinal cord and controlling the immune response peripherally [96].
Even though additional clinical data are required, these results highlighted the key role of
HuR in the initial pathogenesis of MS, during the initiation of the inflammatory process.
5. Pathophysiological Role of nELAV
Growing evidence indicates the prominent role of the neuron-specific members of the
ELAV family, the nELAV (HuD, HuC, HuB), in the development of neurodegenerative dis-
orders [96]. Through their mRNA-stabilizing activities, neuron-specific ELAVs (HuB, HuC,
HuD) modulate neuronal development, participate in synaptic plasticity mechanisms in the
CNS, promote the regeneration of peripheral nerves, and accelerate neuronal differentiation
and axonal outgrowth. HuD, the best-studied member of the nELAVs, demonstrated its role
in promoting neuroprotection through the regulation of brain-derived neurotrophic factor
(BDNF) and GAP43 [89,97]. HuD target mRNAs are associated with several neurological
disorders, including neurodegenerative disorders such as Alzheimer’s, Huntington’s, and
Parkinson’s disease, mood disorders, epilepsy, schizophrenia, and intellectual disabilities,
such as Rett syndrome [26]. Fewer data are available for the physiopathological role of HuB
and HuC. HuB has been associated with schizophrenia and autism spectrum disorder. HuC
single mutant and haplo-insufficient heterozygous mutant are associated with spontaneous
epilepsy. More recent studies correlate HuB and HuC with mood disorders. A subset of
HuC binding sites was mapped to the 3′ UTRs of genes involved in pathways regulating
glutamate pathway, a major excitatory neurotransmitter in the brain [20]. HuB and HuC
silencing promotes neuron generation in the CA3 hippocampal region in a mice model
of depression [98]. Other studies showed that mHuB and mHuC induced the ectopic ex-
pression of neuronal markers, whereas the dominant-negative forms of mHuB and mHuC
suppressed the differentiation of CNS motor neurons. Importantly, evidence indicates that
ELAV members act in concert. An interplay was demonstrated between HuR and nELAV
RBPs in neuronal differentiation in vitro, through which the appearance of nELAV in neu-
roblasts downregulated HuR expression [99]. An imbalanced nELAV/HuR protein ratio in
the nervous system could on one hand augment inflammatory and immune phenomena,
and on the other hand promote axon degeneration. From these observations, all ELAV
proteins are involved in neuronal differentiation in the mammalian nervous system [100],
and proper neuronal development and maintenance appear to be strictly related to the
control of proinflammatory responses. In recent years, the role of neuroinflammation in
the onset and promotion of neurological and neurodegenerative disorders has emerged,
making ELAVs valuable therapeutic targets.
6. Conclusions
Hu proteins represent a heterogeneous family of proteins characterized by different
physiological functions. HuR is ubiquitously expressed in different tissues, and for this
reason its role has been investigated in different pathologies [101]. HuR can simultaneously
modulate the mRNAs involved in inflammatory and regenerative phenomena, which
makes it an innovative and promising target. The contribution of HuR in several diseases
has been postulated, but its exact role is still poorly understood. At the same time, the
variability and the lack of information about the complete pharmacological and physio-
Int. J. Mol. Sci. 2021, 22, 10394 8 of 12
logical profile of Hu proteins limits the development of specific treatments. Glia–neuron
interaction is a novel target for innovative therapies. Indeed, microglia can communicate
with neurons through the release of several mediators (i.e., growth factors, cytokines) or
through direct contact (i.e.,: Notch-1 pathway). Hence, a sort of communication between
Hu family members could exist, and could be modified based on the CNS environment.
Investigating the robust anti-inflammatory capability of HuR, together with the neuronal
effects of nELAV, could represent an important step towards a better understanding of
the pathophysiological role of these proteins, and offer a potential target for novel drug
candidates.
Table 1. In vivo and in vitro investigations on the pathological role of HuR.
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